EEF1A2 and cancer: While AM51.1 demonstrates dual recognition on O-glycans of STn and α2,6-sialylated poly-N-acetyllactosamine structures, AM52.1 excels in its precise targeting of the cancer-associated STn antigen, overcoming a key limitation of previous anti-STn antibodies that often displayed cross-reactivity with structurally related glycans.